Seelos therapeutics doses first patient in part 2 of a registrational study of sls-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in patients with major depressive disorder

New york, july 6, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced dosing of the first patient in part 2, the double-blind, placebo-controlled cohort, of its registrational proof of concept study of sls-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior (asib) in patients with major depressive disorder (mdd). "the goal of the development of sls-002 in treating suicidal patients is to radically change the current standard of care.
SEEL Ratings Summary
SEEL Quant Ranking